If you've researched GLP-1 medications online, you've run into two versions of the same molecules: the brand-name products, and "compounded" versions often offered at lower prices through telehealth. They are not the same thing, and the difference is more than cosmetic — it's regulatory, it's clinical, and in the last year it has changed significantly. This article lays out the real distinction, honestly, so you can make an informed decision rather than a confused one.

A note on honesty up front: this is a space where a lot of marketing blurs the line between these two things. We're going to draw the line clearly, including the parts that don't flatter the compounded option, because you deserve the actual picture.

What "brand-name" means

The brand-name GLP-1 products — semaglutide sold as Ozempic and Wegovy, tirzepatide sold as Mounjaro and Zepbound — are FDA-approved drugs. That means each went through the FDA's full premarket review for safety, effectiveness, and manufacturing quality before it could be sold. When you get one of these, you're getting a product the FDA has evaluated and a manufacturing process the FDA oversees. The tradeoff is cost: without insurance, branded products commonly run over $1,000 a month.

What "compounded" means — and doesn't

A compounded medication is prepared by a licensed pharmacy for an individual patient, rather than mass-manufactured and FDA-approved as a finished product. Compounding is a long-established, legitimate part of pharmacy — it exists so patients who need a customized formulation (a different concentration, an allergen removed, a form they can tolerate) can get one.

But here is the distinction that matters most, and that the marketing most often obscures: compounded semaglutide and tirzepatide are not FDA-approved. The active ingredient is the same molecule found in the approved branded drugs, but the compounded product has not undergone the FDA's review for safety, effectiveness, and quality. "Same active ingredient" is not the same as "same product," and it is not the same as "FDA-approved." Anyone implying otherwise is misrepresenting the single most important fact about these medications — and notably, suggesting that compounded and approved products are equivalent is exactly what has drawn FDA warning letters to telehealth companies.

What changed in 2024–2025: the shortage pathway closed

This is the part most articles are out of date on, so here's the current picture.

For a couple of years, compounded semaglutide and tirzepatide were widely available because both drugs were on the FDA's official drug shortage list. Under federal law, a shortage listing temporarily permits pharmacies to compound copies of an otherwise-unavailable drug. That's what powered the boom in low-cost compounded GLP-1s.

That window has closed. The FDA determined the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in February 2025, and the enforcement grace periods ended in 2025. With the shortages resolved, the shortage-based justification for routinely compounding copies of these drugs no longer applies. In April 2026, the FDA went a step further, proposing to formally exclude these molecules from the pathway that allowed large-scale "outsourcing facility" compounding — reinforcing a clear regulatory direction: when an FDA-approved drug is available, the approved drug is the default.

Where compounding still fits — narrowly

Compounding of these medications hasn't vanished, but the lawful basis for it has narrowed to what it was always fundamentally meant to be: patient-specific compounding for a documented, individual clinical need — not simply a cheaper copy of the branded drug. A licensed pharmacy compounding for a specific patient with a genuine clinical justification (for example, a documented need for a formulation the branded product doesn't offer) operates under a different, still-valid legal framework. What the current rules explicitly do not accept as justification, on their own, are preference or cost savings.

The practical upshot for you as a patient: the presence of compounded GLP-1 in a provider's offering isn't automatically a red flag — legitimate patient-specific compounding exists — but it does mean you should expect a real clinical process behind it, and a provider who is transparent about the not-FDA-approved status rather than one who implies the compounded product is just a discount version of the brand.

How to evaluate this for yourself

A few honest questions to bring to any provider offering compounded GLP-1:

  • Are they clear and upfront that the compounded product is not FDA-approved? (Transparency here is a good sign; obscuring it is a bad one.)
  • Is there a genuine clinical evaluation behind the prescription, or does the process feel like a checkout with a medical form attached? (We cover what a real evaluation looks like in our article on provider-reviewed care.)
  • Are they making honest claims, or implying the compounded product is identical or equivalent to the branded drug? (The latter is precisely what regulators have flagged.)
  • Do they discuss the real risks — including that compounded products haven't had the FDA's safety-and-efficacy review?

Where care fits

The honest bottom line: both branded and compounded pathways exist, they are genuinely different, and the right choice depends on your clinical situation, your circumstances, and a real conversation with a provider who will tell you the truth about the tradeoffs — not sell you a simplified version.

That's the model Cypress is built around: a licensed provider reviews your history and your goals and helps determine what's appropriate for you, with transparency about what you're getting. If you want to understand what that review involves, you can learn how provider-reviewed care works.